Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Nabriva Therape Ads (NBRV)

Nabriva Therape Ads (NBRV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,285,812
  • Shares Outstanding, K 945,450
  • Annual Sales, $ 9,660 K
  • Annual Income, $ -114,780 K
  • 60-Month Beta 2.31
  • Price/Sales 12.86
  • Price/Cash Flow N/A
  • Price/Book 27.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.33
  • Number of Estimates 4
  • High Estimate -0.28
  • Low Estimate -0.41
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +19.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.16 +17.24%
on 01/07/20
1.65 -17.58%
on 01/22/20
+0.04 (+3.03%)
since 12/27/19
3-Month
1.16 +17.24%
on 01/07/20
2.23 -39.01%
on 11/13/19
-0.43 (-24.02%)
since 10/28/19
52-Week
1.16 +17.24%
on 01/07/20
3.27 -58.41%
on 03/21/19
-0.57 (-29.53%)
since 01/28/19

Most Recent Stories

More News
Will Nabriva Therapeutics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.

NBRV : 1.36 (-0.73%)
Nabriva Therapeutics Receives FDA Acknowledgement of New Drug Application Resubmission for Intravenous CONTEPO(TM) (fosfomycin) for Injection

Nabriva Therapeutics plc (NASDAQ: NBRV), a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced that the U.S....

NBRV : 1.36 (-0.73%)
Nabriva Therapeutics Announces $20 Million Registered Direct Offering

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that...

NBRV : 1.36 (-0.73%)
Nabriva Therapeutics Resubmits New Drug Application for Intravenous CONTEPO(TM) (fosfomycin) for Injection

-Nabriva anticipates a six-month review period by the Food and Drug Administration

NBRV : 1.36 (-0.73%)
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that...

NBRV : 1.36 (-0.73%)
Nabriva Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that...

NBRV : 1.36 (-0.73%)
Nabriva Therapeutics Commends the CDC on the 2019 Antibiotic Resistance Threats Report, Highlighting the Need for New Antibiotics Aligned with Antibiotic Stewardship

-- S. pneumoniae continues to be designated by the CDC as "Serious Threat" underscoring need for rapid detection and prevention strategies, particularly in community setting

NBRV : 1.36 (-0.73%)
Nabriva Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

-More than 200 hospital formulary reviews of XENLETA(TM) scheduled before the end of the year-

NBRV : 1.36 (-0.73%)
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that...

NBRV : 1.36 (-0.73%)
Nabriva Therapeutics to Report Third-Quarter 2019 Financial Results on November 12, 2019

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that...

NBRV : 1.36 (-0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NBRV with:

Business Summary

Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins,...

See More

Key Turning Points

2nd Resistance Point 1.46
1st Resistance Point 1.41
Last Price 1.36
1st Support Level 1.33
2nd Support Level 1.30

See More

52-Week High 3.27
Fibonacci 61.8% 2.46
Fibonacci 50% 2.21
Fibonacci 38.2% 1.97
Last Price 1.36
52-Week Low 1.16

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar